Noetik is an AI-native biotech using advanced machine learning and proprietary data to discover and develop precision cancer therapies. The founding team includes key leaders from Recursion and the Parker Institute for Cancer Immunotherapy, namely Ron Alfa MD, PhD (CEO), Jacob Rinaldi, PhD (CSO), Lacey Padron, PhD, (CTO), with a track record of building technology enabled platforms and advancing drugs from discovery to clinical development. The team has built one of the most significant proprietary multimodal lung cancer datasets for machine learning, and demonstrated target discovery using self supervised learning models.